Choate Investment Advisors Has $4.29 Million Stock Holdings in Novartis AG $NVS

Choate Investment Advisors raised its holdings in shares of Novartis AG (NYSE:NVS) by 40.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,147 shares of the company’s stock after acquiring an additional 8,909 shares during the period. Choate Investment Advisors’ holdings in Novartis were worth $4,294,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Todd Asset Management LLC raised its position in shares of Novartis by 5.8% during the 3rd quarter. Todd Asset Management LLC now owns 439,879 shares of the company’s stock valued at $56,411,000 after acquiring an additional 23,978 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Novartis by 5.5% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 132,536 shares of the company’s stock valued at $17,001,000 after acquiring an additional 6,924 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of Novartis by 1.7% during the 3rd quarter. Fisher Asset Management LLC now owns 7,239,366 shares of the company’s stock valued at $928,376,000 after acquiring an additional 117,952 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Novartis by 18.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 537,543 shares of the company’s stock valued at $68,935,000 after acquiring an additional 82,226 shares during the last quarter. Finally, BXM Wealth LLC raised its position in shares of Novartis by 726.9% during the 4th quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock valued at $5,903,000 after acquiring an additional 37,639 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on NVS shares. DZ Bank cut shares of Novartis from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a research report on Thursday, February 12th. Citigroup reissued a “buy” rating on shares of Novartis in a research report on Thursday, February 5th. Sanford C. Bernstein raised shares of Novartis to a “hold” rating in a research report on Thursday, March 19th. Finally, TD Cowen reissued a “hold” rating on shares of Novartis in a research report on Tuesday, February 17th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $141.20.

Novartis Trading Up 0.1%

NVS opened at $152.14 on Monday. The stock has a market capitalization of $290.31 billion, a P/E ratio of 21.80, a P/E/G ratio of 2.67 and a beta of 0.46. Novartis AG has a 12 month low of $111.06 and a 12 month high of $170.46. The firm’s fifty day simple moving average is $150.02 and its 200 day simple moving average is $145.99. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.96.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, April 27th. The company reported $1.99 EPS for the quarter, missing the consensus estimate of $2.11 by ($0.12). The company had revenue of $13.52 billion during the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The company’s revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.28 earnings per share. As a group, research analysts anticipate that Novartis AG will post 8.84 EPS for the current fiscal year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.